Fed. Circ. Explains Rule While Upholding Merck PTAB Loss
By Ryan Davis · October 30, 2025, 8:14 PM EDT
The Federal Circuit sided with generics makers Thursday and upheld the Patent Trial and Appeal Board's invalidation of claims in two Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, while clarifying...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login